Paul Wallace
Director/Miembro de la Junta en Stroma Biosciences Ltd. .
Cargos activos de Paul Wallace
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Stroma Biosciences Ltd.
Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | Director/Miembro de la Junta | 01/01/2021 | - |
Historial de carrera de Paul Wallace
Antiguos cargos conocidos de Paul Wallace.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
MEDIVIR AB | Corporate Officer/Principal | 01/01/2000 | 28/02/2015 |
Formación de Paul Wallace.
University of Cambridge | Doctorate Degree |
Estadísticas
Internacional
Reino Unido | 3 |
Suecia | 2 |
Operativa
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Director/Board Member | 1 |
Sectorial
Health Technology | 2 |
Consumer Services | 2 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
MEDIVIR AB | Health Technology |
Empresas privadas | 1 |
---|---|
Stroma Biosciences Ltd.
Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | Commercial Services |
- Bolsa de valores
- Insiders
- Paul Wallace
- Experiencia